Neurosteroids and Ischemic Stroke: Progesterone a Promising Agent in Reducing the Brain Injury in Ischemic Stroke

被引:9
作者
Andrabi, Syed Suhail [1 ]
Parvez, Suhel [1 ]
Tabassum, Heena [1 ]
机构
[1] Jamia Hamdard, Dept Med Elementol & Toxicol, New Delhi 110062, India
关键词
progesterone; stroke; model; rat; mice; ischemia; neuroprotection; CEREBRAL-ARTERY OCCLUSION; NEUROACTIVE STEROIDS; OXIDATIVE STRESS; SPINAL-CORD; SIGMA-1; RECEPTOR; NERVOUS-SYSTEM; THERAPEUTIC TARGETS; CLINICAL-TRIAL; WOBBLER MOUSE; GLIAL-CELLS;
D O I
10.1615/JEnvironPatholToxicolOncol.2017017156
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Progesterone (P4), a well-known neurosteroid, is produced by ovaries and placenta in females and by adrenal glands in both sexes. Progesterone is also synthesized by central nervous system (CNS) tissues to perform various vital neurological functions in the brain. Apart from performing crucial reproductive functions, it also plays a pivotal role in neurogenesis, regeneration, cognition, mood, inflammation, and myelination in the CNS. A substantial body of experimental evidence from animal models documents the neuroprotective role of P4 in various CNS injury models, including ischemic stroke. Extensive data have revealed that P4 elicits neuroprotection through multiple mechanisms and systems in an integrated manner to prevent neuronal and glial damage, thus reducing mortality and morbidity. Progesterone has been described as safe for use at the clinical level through different routes in several studies. Data regarding the neuroprotective role of P4 in ischemic stroke are of great interest due to their potential clinical implications. In this review, we succinctly discuss the biosynthesis of P4 and distribution of P4 receptors (PRs) in the brain. We summarize our work on the general mechanisms of P4 mediated via the modulation of different PR and neurotransmitters. Finally, we describe the neuroprotective mechanisms of P4 in ischemic stroke models and related clinical prospects.
引用
收藏
页码:191 / 205
页数:15
相关论文
共 121 条
[31]   Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations [J].
Fisher, Marc ;
Feuerstein, Giora ;
Howells, David W. ;
Hurn, Patricia D. ;
Kent, Thomas A. ;
Savitz, Sean I. ;
Lo, Eng H. .
STROKE, 2009, 40 (06) :2244-2250
[32]   Ovarian hormones, aging and stress on hippocampal synaptic plasticity [J].
Foy, Michael R. .
NEUROBIOLOGY OF LEARNING AND MEMORY, 2011, 95 (02) :134-144
[33]   Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments [J].
George, Paul M. ;
Steinberg, Gary K. .
NEURON, 2015, 87 (02) :297-309
[34]   Neuroactive steroids, their metabolites, and neuroinflammation [J].
Giatti, Silvia ;
Boraso, Mariaserena ;
Melcangi, Roberto Cosimo ;
Viviani, Barbara .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2012, 49 (03) :R125-R134
[35]  
Gibson CL, 2014, BRAIN 7, V134, P2125
[36]   Is Progesterone a Candidate Neuroprotective Factor for Treatment following Ischemic Stroke? [J].
Gibson, Claire L. ;
Coomber, Ben ;
Rathbone, James .
NEUROSCIENTIST, 2009, 15 (04) :324-332
[37]   Progesterone: Review of safety for clinical studies [J].
Goletiani, Nathalie V. ;
Keith, Diana R. ;
Gorsky, Sara J. .
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2007, 15 (05) :427-444
[38]   Progesterone prevents mitochondrial dysfunction in the spinal cord of wobbler mice [J].
Gonzalez Deniselle, Maria Claudia ;
Cecilia Carreras, Maria ;
Garay, Laura ;
Gargiulo-Monachelli, Gisella ;
Meyer, Maria ;
Jose Poderoso, Juan ;
De Nicola, Alejandro F. .
JOURNAL OF NEUROCHEMISTRY, 2012, 122 (01) :185-195
[39]   Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets [J].
Hasegawa, Sae ;
Kasubuchi, Mayu ;
Terasawa, Kazuya ;
Kimura, Ikuo .
CURRENT DRUG TARGETS, 2016, 17 (10) :1189-1197
[40]   σ-1 Receptor Modulation of Acid-Sensing Ion Channel a (ASIC1a) and ASIC1a-Induced Ca2+ Influx in Rat Cortical Neurons [J].
Herrera, Yelenis ;
Katnik, Christopher ;
Rodriguez, Jael D. ;
Hall, Aaron A. ;
Willing, Alison ;
Pennypacker, Keith R. ;
Cuevas, Javier .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (02) :491-502